Cleviprex Emulsion
Product Images NDC 10122-611

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Cleviprex (NDC 10122-611). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chiesi Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clevidipine Structure And Formula (Cleviprex 1)

Chemical structure of clevipidine, the active ingredient in Cleviprex .5 mg/mL intravenous emulsion by Chiesi USA, Inc. The diagram shows the molecular formula C21H23Cl2NO6 with atoms and bonds depicted in a two-dimensional format.*

FDA Label Image

Package Label (Principal Display Panel)

Cleviprex injectable emulsion 0.5 mg/mL (50 mg/100 mL) label for intravenous use. The label includes dosing warnings, storage instructions to refrigerate at 2-8°C, and a prominent orange box advising to invert the vial gently several times before use. Manufactured by Chiesi USA, Inc.*

FDA Label Image

Package Label (Principal Display Panel)

Packaging label for Cleviprex (clevidipine) injectable emulsion, 50 mg/100 mL (0.5 mg/mL) by Chiesi USA, Inc. The label includes storage instructions, contents including the active ingredient clevidipine and inactive excipients, and important usage warnings. The label indicates the product is for intravenous use only, single use vial, and includes barcodes and manufacturer information.*

FDA Label Image

Package Label (Principal Display Panel)

Cleviprex 0.5 mg/mL (50 mg/100 mL) injectable emulsion carton for intravenous use, containing 10 single-use vials. Label shows the brand name, generic name clevidipine, dosage strength, and manufacturer Chiesi USA, Inc. The label includes storage instructions, contents, and a barcode.*

FDA Label Image

Figure 1. Mean Change In Systolic Blood Pressure (mmhg) During 30-minute Infusion, Escape-1 (preoperative) (Cleviprex 2)

A line graph depicting the mean change from baseline in systolic blood pressure (mmHg) over time (minutes) for two groups: clevidipine and placebo. The graph shows a greater reduction in systolic blood pressure from baseline over 30 minutes for clevidipine compared to placebo.*

FDA Label Image

Figure 2. Mean Change In Systolic Blood Pressure (mmhg) During 30-minute Infusion, Escape-2 (postoperative) (Cleviprex 3)

A line graph showing the mean change from baseline in systolic blood pressure (mmHg) over 30 minutes for Cleviprex (clevidipine) compared to placebo. The graph depicts a greater decrease in systolic blood pressure with clevidipine than placebo over time, with a note that placebo group decline reflects patient dropout during infusion.*

FDA Label Image

Figure 3. Mean Change In Heart Rate (bpm) During 30-minute Infusion, Escape-1 (preoperative) (Cleviprex 4)

A line graph showing the mean change from baseline in heart rate (beats per minute) over 30 minutes for clevidipine and placebo groups. The clevidipine group shows an increase in heart rate, while the placebo group shows a slight decrease over time.*

FDA Label Image

Figure 4. Mean Change In Heart Rate (bpm) During 30-minute Infusion, Escape-2 (postoperative) (Cleviprex 5)

A line graph showing mean change from baseline heart rate (beats per minute) over 30 minutes for clevidipine and placebo. The graph plots heart rate on the vertical axis and time in minutes on the horizontal axis, with separate lines illustrating heart rate changes for clevidipine and placebo groups.*

FDA Label Image

Figure 5. Mean Percent Change In Sbp (%) During The First 30 Minutes Of Infusion, Velocity (severe Hypertension) (Cleviprex 6)

A line graph depicting mean percent change from baseline systolic blood pressure over time in minutes for clevidipine. The graph shows a trend of decreasing systolic blood pressure from 0 to 30 minutes after administration.*

FDA Label Image

Package Label (Principal Display Panel)

Cleviprex 0.5 mg/mL injectable emulsion vial label for clevidipine by Chiesi USA, Inc. The label includes product usage instructions, storage conditions (refrigerate 2-8°C), and warnings such as not freezing and allergies to soy or eggs. The label is primarily white with black and orange text and contains barcodes, NDC 10122-610-01, and a note to invert the vial gently before use.*

FDA Label Image

Package Label (Principal Display Panel)

Label for Cleviprex (clevidipine) injectable emulsion, 25 mg/50 mL (0.5 mg/mL), by Chiesi USA, Inc. The label indicates it is for intravenous use only, single use vial, and includes storage, content, and usage warnings. The label features the brand and generic names prominently with a barcode and manufacturer information.*

FDA Label Image

Package Label (Principal Display Panel)

Cleviprex 0.5 mg/mL injectable emulsion label for intravenous use showing a 25 mg/50 mL strength. The label indicates 10 single-use vials per carton, produced by Chiesi USA, Inc. The product name, generic name clevidipine, dosage form, strength, and labeler are clearly displayed along with storage instructions and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.